BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Oncology Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.85+0.03 (+1.06%)
Close on Oct 19, 2026
- Market cap
- $228.15M
- P/E (TTM)
- –
- Dividend yield
- –
BridgeBio Oncology Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -115.3%
Financial strength
- Current ratio
- 4.69
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 104.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.71
- Dividend yield
- –